Leukemia

Startup with U-M technology goes public

Date Visible: 
Thursday, November 12, 2015 - 12:00

Kura Oncology Inc., a clinical stage biopharmaceutical company that develops therapies for cancer patients, is now trading on the NASDAQ after an initial public offering.

New finding offers clues for blocking cancer gene

Date Visible: 
Tuesday, October 27, 2015 - 12:00

A new study suggests a potential new way to block one of the most common cancer-causing genes, without causing severe side effects.

Patient Education Videos

Getting Ready for Discharge After Bone Marrow Transplant

 

Researchers unravel mystery of how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts

Date Visible: 
Tuesday, December 3, 2013 - 09:45
Researchers at the Children's Medical Center Research Institute at UT Southwestern, the University of California at San Francisco and the University of Michigan Comprehensive Cancer Center have discovered how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts.

Ponatinib acts against the most resistant types of chronic myeloid leukemia

Date Visible: 
Wednesday, December 5, 2012 - 15:00
Ponatinib acts against the most resistant types of chronic myeloid leukemia based on the results of a Phase I Trial, reported in the New England Journal of Medicine

Time to Heal

After Sean Dush finished the treatment for his ALL, he had a decision to make. His treatment protocol for ALL included maintenance therapy for three years to give him the best chance of being cured. But with long-term treatment comes long-term side effects.

Pages